Bristol Myers` bowel disease drug fails in late-stage study
NEW YORK, March 1 (Reuters) - A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co (BMY.N) of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp.
Sun Pharmaceutical Industries on Friday said its subsidiary has received approval from the US health regulator to market a generic medication used in the treatment of multiple myeloma. The company has received final approval from the US Food and Drug Administration (USFDA) for the generic lenalidomide capsules in multiple strengths, Sun Pharma said in a statement.
An antitrust litigation was filed against several generic pharmaceutical companies including Dr Reddy's Laboratories Ltd, Celgene and Bristol Myers Squibb in the US on Tuesday.
Another key drug from Bristol Myers Squibb’s Celgene buyout might be on its way to an additional indication after an interim analysis showed the therapy boosted red blood cell transfusion independence in patients with a blood disorder during a phase 3 trial.
Scholar Rock has gone longer without a permanent CEO than their last hire was in the position—by almost two months. But that’s changing, with the biotech landing a new executive to lead its rebounding strategy.
An experimental cancer immunotherapy developed by biotechnology company Jounce Therapeutics didn’t help shrink lung cancer tumors in a Phase 2 trial, prompting the company Tuesday to cancel plans to advance it into late-stage testing.
Celgene Corp's Reblozyl® (luspatercept-aamt) Receives Approval in US
Filed by former Celgene shareholders last June, the suit hinges on a $6.4 billion Contingent Value Rights (CVR) agreement that evaporated when one of three drugs at the center of the megadeal—the CAR-T non-Hodgkin lymphoma treatment Breyanzi—failed to snag FDA approval by a Dec. 31, 2020, deadline.